Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154.

Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

Author information

1
National Cancer Institute, Bethesda, MD 20892, USA.

Abstract

While no genome-wide pharmacogenetics study has yet been published, the field of pharmacogenetics is moving towards exploratory, large-scale analyses of the interaction between genetic variation and drug treatment. The Drug Metabolizing Enzymes and Transporters (DMET) platform offers a standardized set of 1936 variants in 225 genes related to drug absorption, distribution, metabolism and elimination that is useful to scan the genome for previously unknown associations between variation in absorption, distribution, metabolism and elimination genes and pharmacokinetic and pharmacodynamic outcomes of drug treatment. The purpose of this review is to put the DMET platform into context within the current study designs that have been used in pharmacogenetics, and to explore the role that DMET has played - and will play - in future pharmacogenetics studies.

PMID:
20017675
DOI:
10.2217/pgs.09.154
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center